has been an entrepreneur and operator for over 15 years. Most recently he founded Vessix, a flexible B2B payment solution provider for the aviation industry. Vessix was accepted into a tech accelerator (LaunchPad LA) at the end of 2012. In 2013 the company from Colorado to Los Angeles and began operations. Vessix is an FBO Management/POS platform + virtual credit card issuing business in private aviation. Vessix built a SaaS software platform, pilot app for making virtual card payments to vendors. Previously he worked at PRS Assets and Merrill Lynch.
is a CPA with over 20 years of experience. David’s real-world experience includes over ten years with a Big 4 Public CPA firm and ten years working in various corporate positions including Director, Controller and CFO. David has help numerous companies with initial public offerings, reverse mergers, SEC compliance and mergers and acquisitions. David graduated from Benedictine University in Lisle, Illinois with a bachelor’s degree in accounting and became a CPA in 1994.
Secretary and Treasurer
JJ began as an advocate for cannabis over 20 years ago. He has been active in the education and cultivation of the Industry early in its development. Exploring the emerging industry of dispensing Medical Marijuana in Colorado, in 2008 he launched a MMJ Delivery Service in NW Colorado. This molded into a Brick & Mortar Retail location for Medical and Recreational Marijuana, with an Infused Product Manufacturer License & Large Grow Facility. In 2011, he launched a business focusing on the accessory market of the Cannabis Industry. For the last 6 years, he has co-owned Sand Gallery, Inc., a High-End Gallery, Glass-Blowing Studio, and Vape Shop. JJ focuses on the development of products in the cannabis space focused on the areas of branded, retail and medicinal areas of the industry.
Dr James Mulé
Dr. Mulé is Associate Center Director, the U.S. Sen ator Connie Mack (ret.) & Family Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. He is recognized for his research and clinical trial contributions to cancer immunoth erapy, particularly in melanoma. His translational work in this area has helped to develop new treatments for advanced cancer patients. He has published nearly 200 articles. Dr. Mulé serves on Advisory Boards of numerous biotechnology and pharma companies as well as investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac, Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select BioVenture Partners, Noble Life Science Partners, KB Capital Management, among others). Dr. Mulé remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A). Dr. Mulé also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). Dr. Mulé received his professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal post-graduate training at the Surgery Branch , Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Dr. Mulé moved to Palo Al to, CA, where he helped to launch and scientifically direct two biotechnology companies and was also an adjunct professor at Stanford University. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endo wed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.
Dr. Raymond Urbanski
Dr. Raymond W. Urbanski, M.D., Ph.D. has been Chief Medical Officer at GT Biopharma, Inc. since September 2017. Dr. Urbanski oversees the development of key products in GT Biopharma’s product pipeline, including its platform targeted immunotherapy BiKE and TriKE technologies. Previously, he served as the Chief Medical Officer of MannKind Corp. from August 10, 2015 until September 29, 2017 and its Corporate Vice President until September 2017. Dr. Urbanski led MannKind’s overall drug development activities and is a member of the Executive Leadership Team. Previously, he served as Chief Medical Officer and Senior Director of oncology research and development at Pfizer Inc. (PFE). Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products. He served as the Vice President and Medical Head of the Established Products Business Unit at Pfizer since 2008 which he built into a global business. From 2004 to 2008, he held various positions in the Pfizer Global Pharmaceutics Group. He has extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor and tremelimumab. In addition to his role with Pfizer, he served as Chief Medical Officer of Mylan Inc., and Senior Director of US Medical Affairs for Aventis. He served as the Chief Medical Officer at Cymabay Therapeutics, Inc. (alternate name, Metabolex, Inc.) since October 2011. He served as the Vice President for Research and Development at Suntory Pharmaceutical, Inc. from 2001 to 2004 and its CMO. He held various positions at Aventis and AstraZeneca from 1998 to 2001. Dr. Urbanski received his Ph.D. in pharmacology and Toxicology and his M.D. from the University of Medicine and Dentistry of New Jersey.
Professor Oded Shoseyov
is a Co-Founder of SP Nano Ltd. and serves as its Scientific Advisor. Prof. Shoseyov is the Scientific Founder of CBD Technologies., FuturaGene, Melodea and Bondex. He founded Collplant Holdings Ltd. in 2004 and has been its Chief Scientist Officer since August 2008. He serves as the Chief Scientist at CBD Technologies Ltd. Prof. Shoseyov He is a Founder of Fulcrum SP Ltd. Prof. Shoseyov is a Faculty Member of the Institute of Plant Science and Genetics in Agriculture and the Otto Warburg Center for Agricultural Biotechnology at the Faculty of Agriculture, Food and Environmental Quality Sciences of the Hebrew University of Jerusalem. His main field of research is plant molecular biology and biotechnology. He has extensive experience with genetic engineering of plants, protein engineering and nano-biotechnology. He serves as a Member of Advisory Board at EQUI-nom Ltd. Prof. Shoseyov serves as a Member of Scientific Advisory Board of FuturaGene Plc (now known as FuturaGene, LTD.). He served as a Director of Collplant Holdings Ltd. from May 20, 2010 to October 2016. He is an invited Speaker at many scientific conferences and has published extensively. He is the Inventor Or Co-inventor of more than 14 patents, 9 of which relate directly to CBD Technologies business. He has authored or co-authored more than 160 scientific publications and is the inventor or co-inventor of 42 patents. He has received numerous awards and appointments for his research in agricultural biotechnology. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002 and the 1999 Kay Award for Innovative and Applied Research. He received his B.S. with Excellence in 1981, his M.S. with Excellence in 1983 and his Ph.D. summa cum laude in 1988 from the Hebrew University of Jerusalem.
James H. Bailey
is the Founder and Managing General Partner of Velos Partners a technology and consumer fund with offices in Los Angeles and Singapore. James is also the Founder or Bailey Ventures, a cannabis investment company with stakes in industry leading brands like Pax, Eaze, High Times, Bloom Farms and Zynerba. James previously worked at Accel Partnerss, Highland Capital, TA Associates and Upfront Ventures.
Dr. Xiang-Qun (Sean) Xie PhD, EMBA
Associate Dean for Research Innovation at School of Pharmacy and a Professor of Pharmaceutical Sciences/Drug Discovery Institute, and a PI of an integrated Medicinal Chemistry Biology Llaboratory of CompuGroup, BioGroup and ChemGroup (www.CBLigand.org/XieLab) at University of Pittsburgh. He is a member of the Science Advisory Board to the US FDA. He is a Founding Director of Computational Chemical Genomics Screening Center (www.CBLigand.org/CCGS), and a Director/PI of NIH National Center of Excellence for CDAR. (www.CDARCenter.org). He holds joint positions at Dept of Computational Biology and Dept of Structural Biology, and Pitt Cancer Institute MT/DD Program. He is an Editorial Advisory Board member for AAPS Journaland American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology Toxicology. Dr Xie received his MD in Pharmacy from the Second Military Medical University in Shanghai China, PhD in Medicinal Chemistry from the School of Pharmacy, University of Connecticut, and Executive MBA degree, and the Shared Leadership Cohort Development Experience Workshop Training by JPorcari & Associates.